In general, DLBCLs with a GEP signature related to activated B-cell cells (ABC subgroup) have a worse outcome compared to their germinal center B-cell (GCB) counterparts [4–7], and display higher expression levels of MYC and BCL2 [8] and oncogenic addiction to nuclear factor kappa-B (NF-kB) signaling [9]. The gene discussed is BCL2; the disease is aneurysmal bone cyst.